103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine. LRB103 27669 RLC 57233 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine. LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b A BILL FOR
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/401 from Ch. 56 1/2, par. 1401
Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.
LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b
LRB103 27669 RLC 57233 b
A BILL FOR
SB2089LRB103 27669 RLC 57233 b SB2089 LRB103 27669 RLC 57233 b
SB2089 LRB103 27669 RLC 57233 b
1 AN ACT concerning criminal law.
2 Be it enacted by the People of the State of Illinois,
3 represented in the General Assembly:
4 Section 5. The Illinois Controlled Substances Act is
5 amended by changing Sections 204 and 401 as follows:
6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
7 Sec. 204. (a) The controlled substances listed in this
8 Section are included in Schedule I.
9 (b) Unless specifically excepted or unless listed in
10 another schedule, any of the following opiates, including
11 their isomers, esters, ethers, salts, and salts of isomers,
12 esters, and ethers, whenever the existence of such isomers,
13 esters, ethers and salts is possible within the specific
14 chemical designation:
15 (1) Acetylmethadol;
16 (1.1) Acetyl-alpha-methylfentanyl
17 (N-[1-(1-methyl-2-phenethyl)-
18 4-piperidinyl]-N-phenylacetamide);
19 (2) Allylprodine;
20 (3) Alphacetylmethadol, except
21 levo-alphacetylmethadol (also known as levo-alpha-
22 acetylmethadol, levomethadyl acetate, or LAAM);
23 (4) Alphameprodine;
103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 SB2089 Introduced 2/9/2023, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED:
720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/401 from Ch. 56 1/2, par. 1401
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/401 from Ch. 56 1/2, par. 1401
Amends the Illinois Controlled Substances Act. Adds xylazine as a Schedule I controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine.
LRB103 27669 RLC 57233 b LRB103 27669 RLC 57233 b
LRB103 27669 RLC 57233 b
A BILL FOR
720 ILCS 570/204 from Ch. 56 1/2, par. 1204
720 ILCS 570/401 from Ch. 56 1/2, par. 1401
LRB103 27669 RLC 57233 b
SB2089 LRB103 27669 RLC 57233 b
SB2089- 2 -LRB103 27669 RLC 57233 b SB2089 - 2 - LRB103 27669 RLC 57233 b
SB2089 - 2 - LRB103 27669 RLC 57233 b
1 (5) Alphamethadol;
2 (6) Alpha-methylfentanyl
3 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
4 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
5 propanilido) piperidine;
6 (6.1) Alpha-methylthiofentanyl
7 (N-[1-methyl-2-(2-thienyl)ethyl-
8 4-piperidinyl]-N-phenylpropanamide);
9 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
10 (7.1) PEPAP
11 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
12 (8) Benzethidine;
13 (9) Betacetylmethadol;
14 (9.1) Beta-hydroxyfentanyl
15 (N-[1-(2-hydroxy-2-phenethyl)-
16 4-piperidinyl]-N-phenylpropanamide);
17 (10) Betameprodine;
18 (11) Betamethadol;
19 (12) Betaprodine;
20 (13) Clonitazene;
21 (14) Dextromoramide;
22 (15) Diampromide;
23 (16) Diethylthiambutene;
24 (17) Difenoxin;
25 (18) Dimenoxadol;
26 (19) Dimepheptanol;
SB2089 - 2 - LRB103 27669 RLC 57233 b
SB2089- 3 -LRB103 27669 RLC 57233 b SB2089 - 3 - LRB103 27669 RLC 57233 b
SB2089 - 3 - LRB103 27669 RLC 57233 b
1 (20) Dimethylthiambutene;
2 (21) Dioxaphetylbutyrate;
3 (22) Dipipanone;
4 (23) Ethylmethylthiambutene;
5 (24) Etonitazene;
6 (25) Etoxeridine;
7 (26) Furethidine;
8 (27) Hydroxpethidine;
9 (28) Ketobemidone;
10 (29) Levomoramide;
11 (30) Levophenacylmorphan;
12 (31) 3-Methylfentanyl
13 (N-[3-methyl-1-(2-phenylethyl)-
14 4-piperidyl]-N-phenylpropanamide);
15 (31.1) 3-Methylthiofentanyl
16 (N-[(3-methyl-1-(2-thienyl)ethyl-
17 4-piperidinyl]-N-phenylpropanamide);
18 (32) Morpheridine;
19 (33) Noracymethadol;
20 (34) Norlevorphanol;
21 (35) Normethadone;
22 (36) Norpipanone;
23 (36.1) Para-fluorofentanyl
24 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
25 4-piperidinyl]propanamide);
26 (37) Phenadoxone;
SB2089 - 3 - LRB103 27669 RLC 57233 b
SB2089- 4 -LRB103 27669 RLC 57233 b SB2089 - 4 - LRB103 27669 RLC 57233 b
SB2089 - 4 - LRB103 27669 RLC 57233 b
1 (38) Phenampromide;
2 (39) Phenomorphan;
3 (40) Phenoperidine;
4 (41) Piritramide;
5 (42) Proheptazine;
6 (43) Properidine;
7 (44) Propiram;
8 (45) Racemoramide;
9 (45.1) Thiofentanyl
10 (N-phenyl-N-[1-(2-thienyl)ethyl-
11 4-piperidinyl]-propanamide);
12 (46) Tilidine;
13 (47) Trimeperidine;
14 (48) Beta-hydroxy-3-methylfentanyl (other name:
15 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
16 N-phenylpropanamide);
17 (49) Furanyl fentanyl (FU-F);
18 (50) Butyryl fentanyl;
19 (51) Valeryl fentanyl;
20 (52) Acetyl fentanyl;
21 (53) Beta-hydroxy-thiofentanyl;
22 (54) 3,4-dichloro-N-[2-
23 (dimethylamino)cyclohexyl]-N-
24 methylbenzamide (U-47700);
25 (55) 4-chloro-N-[1-[2-
26 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
SB2089 - 4 - LRB103 27669 RLC 57233 b
SB2089- 5 -LRB103 27669 RLC 57233 b SB2089 - 5 - LRB103 27669 RLC 57233 b
SB2089 - 5 - LRB103 27669 RLC 57233 b
1 benzenesulfonamide (W-18);
2 (56) 4-chloro-N-[1-(2-phenylethyl)
3 -2-piperidinylidene]-benzenesulfonamide (W-15);
4 (57) acrylfentanyl (acryloylfentanyl).
5 (c) Unless specifically excepted or unless listed in
6 another schedule, any of the following opium derivatives, its
7 salts, isomers and salts of isomers, whenever the existence of
8 such salts, isomers and salts of isomers is possible within
9 the specific chemical designation:
10 (1) Acetorphine;
11 (2) Acetyldihydrocodeine;
12 (3) Benzylmorphine;
13 (4) Codeine methylbromide;
14 (5) Codeine-N-Oxide;
15 (6) Cyprenorphine;
16 (7) Desomorphine;
17 (8) Diacetyldihydromorphine (Dihydroheroin);
18 (9) Dihydromorphine;
19 (10) Drotebanol;
20 (11) Etorphine (except hydrochloride salt);
21 (12) Heroin;
22 (13) Hydromorphinol;
23 (14) Methyldesorphine;
24 (15) Methyldihydromorphine;
25 (16) Morphine methylbromide;
26 (17) Morphine methylsulfonate;
SB2089 - 5 - LRB103 27669 RLC 57233 b
SB2089- 6 -LRB103 27669 RLC 57233 b SB2089 - 6 - LRB103 27669 RLC 57233 b
SB2089 - 6 - LRB103 27669 RLC 57233 b
1 (18) Morphine-N-Oxide;
2 (19) Myrophine;
3 (20) Nicocodeine;
4 (21) Nicomorphine;
5 (22) Normorphine;
6 (23) Pholcodine;
7 (24) Thebacon.
8 (d) Unless specifically excepted or unless listed in
9 another schedule, any material, compound, mixture, or
10 preparation which contains any quantity of the following
11 hallucinogenic substances, or which contains any of its salts,
12 isomers and salts of isomers, whenever the existence of such
13 salts, isomers, and salts of isomers is possible within the
14 specific chemical designation (for the purposes of this
15 paragraph only, the term "isomer" includes the optical,
16 position and geometric isomers):
17 (1) 3,4-methylenedioxyamphetamine
18 (alpha-methyl,3,4-methylenedioxyphenethylamine,
19 methylenedioxyamphetamine, MDA);
20 (1.1) Alpha-ethyltryptamine
21 (some trade or other names: etryptamine;
22 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
23 3-(2-aminobutyl)indole; a-ET; and AET);
24 (2) 3,4-methylenedioxymethamphetamine (MDMA);
25 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
26 (also known as: N-ethyl-alpha-methyl-
SB2089 - 6 - LRB103 27669 RLC 57233 b
SB2089- 7 -LRB103 27669 RLC 57233 b SB2089 - 7 - LRB103 27669 RLC 57233 b
SB2089 - 7 - LRB103 27669 RLC 57233 b
1 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
2 and MDEA);
3 (2.2) N-Benzylpiperazine (BZP);
4 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
5 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
6 (4) 3,4,5-trimethoxyamphetamine (TMA);
7 (5) (Blank);
8 (6) Diethyltryptamine (DET);
9 (7) Dimethyltryptamine (DMT);
10 (7.1) 5-Methoxy-diallyltryptamine;
11 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
12 (9) Ibogaine (some trade and other names:
13 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
14 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
15 indole; Tabernanthe iboga);
16 (10) Lysergic acid diethylamide;
17 (10.1) Salvinorin A;
18 (10.5) Salvia divinorum (meaning all parts of the
19 plant presently classified botanically as Salvia
20 divinorum, whether growing or not, the seeds thereof, any
21 extract from any part of that plant, and every compound,
22 manufacture, salts, isomers, and salts of isomers whenever
23 the existence of such salts, isomers, and salts of isomers
24 is possible within the specific chemical designation,
25 derivative, mixture, or preparation of that plant, its
26 seeds or extracts);
SB2089 - 7 - LRB103 27669 RLC 57233 b
SB2089- 8 -LRB103 27669 RLC 57233 b SB2089 - 8 - LRB103 27669 RLC 57233 b
SB2089 - 8 - LRB103 27669 RLC 57233 b
1 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
2 (12) Peyote (meaning all parts of the plant presently
3 classified botanically as Lophophora williamsii Lemaire,
4 whether growing or not, the seeds thereof, any extract
5 from any part of that plant, and every compound,
6 manufacture, salts, derivative, mixture, or preparation of
7 that plant, its seeds or extracts);
8 (13) N-ethyl-3-piperidyl benzilate (JB 318);
9 (14) N-methyl-3-piperidyl benzilate;
10 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
11 (also known as N-hydroxy-alpha-methyl-
12 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
13 (15) Parahexyl; some trade or other names:
14 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
15 dibenzo (b,d) pyran; Synhexyl;
16 (16) Psilocybin;
17 (17) Psilocyn;
18 (18) Alpha-methyltryptamine (AMT);
19 (19) 2,5-dimethoxyamphetamine
20 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
21 (20) 4-bromo-2,5-dimethoxyamphetamine
22 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
23 4-bromo-2,5-DMA);
24 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
25 Some trade or other names: 2-(4-bromo-
26 2,5-dimethoxyphenyl)-1-aminoethane;
SB2089 - 8 - LRB103 27669 RLC 57233 b
SB2089- 9 -LRB103 27669 RLC 57233 b SB2089 - 9 - LRB103 27669 RLC 57233 b
SB2089 - 9 - LRB103 27669 RLC 57233 b
1 alpha-desmethyl DOB, 2CB, Nexus;
2 (21) 4-methoxyamphetamine
3 (4-methoxy-alpha-methylphenethylamine;
4 paramethoxyamphetamine; PMA);
5 (22) (Blank);
6 (23) Ethylamine analog of phencyclidine.
7 Some trade or other names:
8 N-ethyl-1-phenylcyclohexylamine,
9 (1-phenylcyclohexyl) ethylamine,
10 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
11 (24) Pyrrolidine analog of phencyclidine. Some trade
12 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
13 PHP;
14 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
15 (26) 2,5-dimethoxy-4-ethylamphetamine
16 (another name: DOET);
17 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
18 (another name: TCPy);
19 (28) (Blank);
20 (29) Thiophene analog of phencyclidine (some trade
21 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
22 2-thienyl analog of phencyclidine; TPCP; TCP);
23 (29.1) Benzothiophene analog of phencyclidine. Some
24 trade or other names: BTCP or benocyclidine;
25 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
26 (30) Bufotenine (some trade or other names:
SB2089 - 9 - LRB103 27669 RLC 57233 b
SB2089- 10 -LRB103 27669 RLC 57233 b SB2089 - 10 - LRB103 27669 RLC 57233 b
SB2089 - 10 - LRB103 27669 RLC 57233 b
1 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
2 3-(2-dimethylaminoethyl)-5-indolol;
3 5-hydroxy-N,N-dimethyltryptamine;
4 N,N-dimethylserotonin; mappine);
5 (31) (Blank);
6 (32) (Blank);
7 (33) (Blank);
8 (34) (Blank);
9 (34.5) (Blank);
10 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
11 (2-methyloctan-2-yl)-6a,7,
12 10,10a-tetrahydrobenzo[c]chromen-1-ol
13 Some trade or other names: HU-210;
14 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
15 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
16 tetrahydrobenzo[c]chromen-1-ol, its isomers,
17 salts, and salts of isomers; Some trade or other
18 names: HU-210, Dexanabinol;
19 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
20 6,6-dimethyl-3-(2-methyloctan-2-yl)-
21 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
22 Some trade or other names: HU-211;
23 (37) (Blank);
24 (38) (Blank);
25 (39) (Blank);
26 (40) (Blank);
SB2089 - 10 - LRB103 27669 RLC 57233 b
SB2089- 11 -LRB103 27669 RLC 57233 b SB2089 - 11 - LRB103 27669 RLC 57233 b
SB2089 - 11 - LRB103 27669 RLC 57233 b
1 (41) (Blank);
2 (42) Any compound structurally derived from
3 3-(1-naphthoyl)indole or
4 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
5 nitrogen atom of the indole ring by alkyl, haloalkyl,
6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
8 2-(4-morpholinyl)ethyl whether or not further substituted
9 in the indole ring to any extent, whether or not
10 substituted in the naphthyl ring to any extent. Examples
11 of this structural class include, but are not limited to,
12 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
13 (43) Any compound structurally derived from
14 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
15 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 in the pyrrole ring to any extent, whether or not
20 substituted in the naphthyl ring to any extent. Examples
21 of this structural class include, but are not limited to,
22 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
23 (44) Any compound structurally derived from
24 1-(1-naphthylmethyl)indene by substitution at the
25 3-position of the indene ring by alkyl, haloalkyl,
26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
SB2089 - 11 - LRB103 27669 RLC 57233 b
SB2089- 12 -LRB103 27669 RLC 57233 b SB2089 - 12 - LRB103 27669 RLC 57233 b
SB2089 - 12 - LRB103 27669 RLC 57233 b
1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
2 2-(4-morpholinyl)ethyl whether or not further substituted
3 in the indene ring to any extent, whether or not
4 substituted in the naphthyl ring to any extent. Examples
5 of this structural class include, but are not limited to,
6 JWH-176;
7 (45) Any compound structurally derived from
8 3-phenylacetylindole by substitution at the nitrogen atom
9 of the indole ring with alkyl, haloalkyl, alkenyl,
10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
12 2-(4-morpholinyl)ethyl, whether or not further substituted
13 in the indole ring to any extent, whether or not
14 substituted in the phenyl ring to any extent. Examples of
15 this structural class include, but are not limited to,
16 JWH-167, JWH-250, JWH-251, and RCS-8;
17 (46) Any compound structurally derived from
18 2-(3-hydroxycyclohexyl)phenol by substitution at the
19 5-position of the phenolic ring by alkyl, haloalkyl,
20 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
21 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
22 2-(4-morpholinyl)ethyl, whether or not substituted in the
23 cyclohexyl ring to any extent. Examples of this structural
24 class include, but are not limited to, CP 47, 497 and its
25 C8 homologue (cannabicyclohexanol);
26 (46.1) Any compound structurally derived from
SB2089 - 12 - LRB103 27669 RLC 57233 b
SB2089- 13 -LRB103 27669 RLC 57233 b SB2089 - 13 - LRB103 27669 RLC 57233 b
SB2089 - 13 - LRB103 27669 RLC 57233 b
1 3-(benzoyl) indole with substitution at the nitrogen atom
2 of the indole ring by an alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl group whether or not further
6 substituted in the indole ring to any extent and whether
7 or not substituted in the phenyl ring to any extent.
8 Examples of this structural class include, but are not
9 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
10 48,098), and RCS-4;
11 (47) (Blank);
12 (48) (Blank);
13 (49) (Blank);
14 (50) (Blank);
15 (51) (Blank);
16 (52) (Blank);
17 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
18 Some trade or other names: 2C-T-7;
19 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
20 trade or other names: 2C-E;
21 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
22 trade or other names: 2C-D;
23 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
24 trade or other names: 2C-C;
25 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
26 or other names: 2C-I;
SB2089 - 13 - LRB103 27669 RLC 57233 b
SB2089- 14 -LRB103 27669 RLC 57233 b SB2089 - 14 - LRB103 27669 RLC 57233 b
SB2089 - 14 - LRB103 27669 RLC 57233 b
1 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
2 trade or other names: 2C-T-2;
3 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
4 Some trade or other names: 2C-T-4;
5 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
6 other names: 2C-H;
7 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
8 trade or other names: 2C-N;
9 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
10 trade or other names: 2C-P;
11 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
12 Some trade or other names: 2C-G;
13 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
14 phenethylamine referred to in subparagraphs (20.1), (53),
15 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
16 (53.8), (53.9), and (53.10) including, but not limited to,
17 25I-NBOMe and 25C-NBOMe;
18 (54) 5-Methoxy-N,N-diisopropyltryptamine;
19 (55) (Blank);
20 (56) (Blank);
21 (57) (Blank);
22 (58) (Blank);
23 (59) 3-cyclopropoylindole with substitution at the
24 nitrogen atom of the indole ring by alkyl, haloalkyl,
25 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
26 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
SB2089 - 14 - LRB103 27669 RLC 57233 b
SB2089- 15 -LRB103 27669 RLC 57233 b SB2089 - 15 - LRB103 27669 RLC 57233 b
SB2089 - 15 - LRB103 27669 RLC 57233 b
1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indole ring to any extent, whether or not
3 substituted on the cyclopropyl ring to any extent:
4 including, but not limited to, XLR11, UR144, FUB-144;
5 (60) 3-adamantoylindole with substitution at the
6 nitrogen atom of the indole ring by alkyl, haloalkyl,
7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indole ring to any extent, whether or not
11 substituted on the adamantyl ring to any extent:
12 including, but not limited to, AB-001;
13 (61) N-(adamantyl)-indole-3-carboxamide with
14 substitution at the nitrogen atom of the indole ring by
15 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
16 cycloalkylethyl, aryl halide, alkyl aryl halide,
17 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indole ring to any extent, whether or not
20 substituted on the adamantyl ring to any extent:
21 including, but not limited to, APICA/2NE-1, STS-135;
22 (62) N-(adamantyl)-indazole-3-carboxamide with
23 substitution at a nitrogen atom of the indazole ring by
24 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
25 cycloalkylethyl, aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or
SB2089 - 15 - LRB103 27669 RLC 57233 b
SB2089- 16 -LRB103 27669 RLC 57233 b SB2089 - 16 - LRB103 27669 RLC 57233 b
SB2089 - 16 - LRB103 27669 RLC 57233 b
1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indazole ring to any extent, whether or not
3 substituted on the adamantyl ring to any extent:
4 including, but not limited to, AKB48, 5F-AKB48;
5 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
6 with substitution at the nitrogen atom of the indole ring
7 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8 cycloalkylethyl, aryl halide, alkyl aryl halide,
9 1-(N-methyl-2-piperidinyl)methyl, or
10 2-(4-morpholinyl)ethyl, whether or not further substituted
11 on the indole ring to any extent, whether or not
12 substituted on the quinoline ring to any extent:
13 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
14 (64) 3-(1-naphthoyl)indazole with substitution at the
15 nitrogen atom of the indazole ring by alkyl, haloalkyl,
16 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
17 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
18 2-(4-morpholinyl)ethyl, whether or not further substituted
19 on the indazole ring to any extent, whether or not
20 substituted on the naphthyl ring to any extent: including,
21 but not limited to, THJ-018, THJ-2201;
22 (65) 2-(1-naphthoyl)benzimidazole with substitution
23 at the nitrogen atom of the benzimidazole ring by alkyl,
24 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25 aryl halide, alkyl aryl halide,
26 1-(N-methyl-2-piperidinyl)methyl, or
SB2089 - 16 - LRB103 27669 RLC 57233 b
SB2089- 17 -LRB103 27669 RLC 57233 b SB2089 - 17 - LRB103 27669 RLC 57233 b
SB2089 - 17 - LRB103 27669 RLC 57233 b
1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the benzimidazole ring to any extent, whether or not
3 substituted on the naphthyl ring to any extent: including,
4 but not limited to, FUBIMINA;
5 (66)
6 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
7 3-carboxamide with substitution on the nitrogen atom of
8 the indazole ring by alkyl, haloalkyl, alkenyl,
9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
11 2-(4-morpholinyl)ethyl, whether or not further substituted
12 on the indazole ring to any extent: including, but not
13 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
14 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
15 indazole-3-carboxamide with substitution on the nitrogen
16 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
19 2-(4-morpholinyl)ethyl, whether or not further substituted
20 on the indazole ring to any extent: including, but not
21 limited to, ADB-PINACA, ADB-FUBINACA;
22 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
23 indole-3-carboxamide with substitution on the nitrogen
24 atom of the indole ring by alkyl, haloalkyl, alkenyl,
25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
26 halide, 1-(N-methyl-2-piperidinyl)methyl, or
SB2089 - 17 - LRB103 27669 RLC 57233 b
SB2089- 18 -LRB103 27669 RLC 57233 b SB2089 - 18 - LRB103 27669 RLC 57233 b
SB2089 - 18 - LRB103 27669 RLC 57233 b
1 2-(4-morpholinyl)ethyl, whether or not further substituted
2 on the indole ring to any extent: including, but not
3 limited to, ADBICA, 5F-ADBICA;
4 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
5 3-carboxamide with substitution on the nitrogen atom of
6 the indole ring by alkyl, haloalkyl, alkenyl,
7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
9 2-(4-morpholinyl)ethyl, whether or not further substituted
10 on the indole ring to any extent: including, but not
11 limited to, ABICA, 5F-ABICA;
12 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
13 methylbutanoate with substitution on the nitrogen atom of
14 the indazole ring by alkyl, haloalkyl, alkenyl,
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
17 2-(4-morpholinyl)ethyl, whether or not further substituted
18 on the indazole ring to any extent: including, but not
19 limited to, AMB, 5F-AMB;
20 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
21 dimethylbutanoate with substitution on the nitrogen atom
22 of the indazole ring by alkyl, haloalkyl, alkenyl,
23 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
24 halide, 1-(N-methyl-2-piperidinyl)methyl, or
25 2-(4-morpholinyl)ethyl, whether or not further substituted
26 on the indazole ring to any extent: including, but not
SB2089 - 18 - LRB103 27669 RLC 57233 b
SB2089- 19 -LRB103 27669 RLC 57233 b SB2089 - 19 - LRB103 27669 RLC 57233 b
SB2089 - 19 - LRB103 27669 RLC 57233 b
1 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
2 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
3 methylbutanoate with substitution on the nitrogen atom of
4 the indole ring by alkyl, haloalkyl, alkenyl,
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
6 halide, 1-(N-methyl-2-piperidinyl)methyl, or
7 2-(4-morpholinyl)ethyl, whether or not further substituted
8 on the indazole ring to any extent: including, but not
9 limited to, MMB018, MMB2201, and AMB-CHMICA;
10 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
11 dimethylbutanoate with substitution on the nitrogen atom
12 of the indole ring by alkyl, haloalkyl, alkenyl,
13 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
14 halide, 1-(N-methyl-2-piperidinyl)methyl, or
15 2-(4-morpholinyl)ethyl, whether or not further substituted
16 on the indazole ring to any extent: including, but not
17 limited to, MDMB-CHMICA;
18 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
19 indazole-3-carboxamide with substitution on the nitrogen
20 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
23 2-(4-morpholinyl)ethyl, whether or not further substituted
24 on the indazole ring to any extent: including, but not
25 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
26 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
SB2089 - 19 - LRB103 27669 RLC 57233 b
SB2089- 20 -LRB103 27669 RLC 57233 b SB2089 - 20 - LRB103 27669 RLC 57233 b
SB2089 - 20 - LRB103 27669 RLC 57233 b
1 3-carboxamide with substitution on the nitrogen atom of
2 the indole ring by alkyl, haloalkyl, alkenyl,
3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
5 2-(4-morpholinyl)ethyl, whether or not further substituted
6 on the indazole ring to any extent: including, but not
7 limited to, APP-PICA and 5-fluoro-APP-PICA;
8 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
9 4-AcO-DMT;
10 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
11 name 5-MeO-MIPT;
12 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
13 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
14 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
15 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
16 (4-HO-MiPT);
17 (82) Fluorophenylpiperazine;
18 (83) Methoxetamine;
19 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
20 ethcathinone).
21 (e) Unless specifically excepted or unless listed in
22 another schedule, any material, compound, mixture, or
23 preparation which contains any quantity of the following
24 substances having a depressant effect on the central nervous
25 system, including its salts, isomers, and salts of isomers
26 whenever the existence of such salts, isomers, and salts of
SB2089 - 20 - LRB103 27669 RLC 57233 b
SB2089- 21 -LRB103 27669 RLC 57233 b SB2089 - 21 - LRB103 27669 RLC 57233 b
SB2089 - 21 - LRB103 27669 RLC 57233 b
1 isomers is possible within the specific chemical designation:
2 (1) mecloqualone;
3 (2) methaqualone; and
4 (3) gamma hydroxybutyric acid; and
5 (4) xylazine.
6 (f) Unless specifically excepted or unless listed in
7 another schedule, any material, compound, mixture, or
8 preparation which contains any quantity of the following
9 substances having a stimulant effect on the central nervous
10 system, including its salts, isomers, and salts of isomers:
11 (1) Fenethylline;
12 (2) N-ethylamphetamine;
13 (3) Aminorex (some other names:
14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
15 4-5-dihydro-5-phenyl-2-oxazolamine) and its
16 salts, optical isomers, and salts of optical isomers;
17 (4) Methcathinone (some other names:
18 2-methylamino-1-phenylpropan-1-one;
19 Ephedrone; 2-(methylamino)-propiophenone;
20 alpha-(methylamino)propiophenone; N-methylcathinone;
21 methycathinone; Monomethylpropion; UR 1431) and its
22 salts, optical isomers, and salts of optical isomers;
23 (5) Cathinone (some trade or other names:
24 2-aminopropiophenone; alpha-aminopropiophenone;
25 2-amino-1-phenyl-propanone; norephedrone);
26 (6) N,N-dimethylamphetamine (also known as:
SB2089 - 21 - LRB103 27669 RLC 57233 b
SB2089- 22 -LRB103 27669 RLC 57233 b SB2089 - 22 - LRB103 27669 RLC 57233 b
SB2089 - 22 - LRB103 27669 RLC 57233 b
1 N,N-alpha-trimethyl-benzeneethanamine;
2 N,N-alpha-trimethylphenethylamine);
3 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
5 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
6 (9) Halogenated amphetamines and
7 methamphetamines - any compound derived from either
8 amphetamine or methamphetamine through the substitution
9 of a halogen on the phenyl ring, including, but not
10 limited to, 2-fluoroamphetamine, 3-
11 fluoroamphetamine and 4-fluoroamphetamine;
12 (10) Aminopropylbenzofuran (APB):
13 including 4-(2-Aminopropyl) benzofuran, 5-
14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
15 benzofuran, and 7-(2-Aminopropyl) benzofuran;
16 (11) Aminopropyldihydrobenzofuran (APDB):
17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
21 (12) Methylaminopropylbenzofuran
22 (MAPB): including 4-(2-methylaminopropyl)
23 benzofuran, 5-(2-methylaminopropyl)benzofuran,
24 6-(2-methylaminopropyl)benzofuran
25 and 7-(2-methylaminopropyl)benzofuran.
26 (g) Temporary listing of substances subject to emergency
SB2089 - 22 - LRB103 27669 RLC 57233 b
SB2089- 23 -LRB103 27669 RLC 57233 b SB2089 - 23 - LRB103 27669 RLC 57233 b
SB2089 - 23 - LRB103 27669 RLC 57233 b
1 scheduling. Any material, compound, mixture, or preparation
2 that contains any quantity of the following substances:
3 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
4 (benzylfentanyl), its optical isomers, isomers, salts, and
5 salts of isomers;
6 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
7 phenylpropanamide (thenylfentanyl), its optical isomers,
8 salts, and salts of isomers.
9 (h) Synthetic cathinones. Unless specifically excepted,
10 any chemical compound which is not approved by the United
11 States Food and Drug Administration or, if approved, is not
12 dispensed or possessed in accordance with State or federal
13 law, not including bupropion, structurally derived from
14 2-aminopropan-1-one by substitution at the 1-position with
15 either phenyl, naphthyl, or thiophene ring systems, whether or
16 not the compound is further modified in one or more of the
17 following ways:
18 (1) by substitution in the ring system to any extent
19 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
20 halide substituents, whether or not further substituted in
21 the ring system by one or more other univalent
22 substituents. Examples of this class include, but are not
23 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
24 (2) by substitution at the 3-position with an acyclic
25 alkyl substituent. Examples of this class include, but are
26 not limited to, 2-methylamino-1-phenylbutan-1-one
SB2089 - 23 - LRB103 27669 RLC 57233 b
SB2089- 24 -LRB103 27669 RLC 57233 b SB2089 - 24 - LRB103 27669 RLC 57233 b
SB2089 - 24 - LRB103 27669 RLC 57233 b
1 (buphedrone); or
2 (3) by substitution at the 2-amino nitrogen atom with
3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
4 inclusion of the 2-amino nitrogen atom in a cyclic
5 structure. Examples of this class include, but are not
6 limited to, Dimethylcathinone, Ethcathinone, and
7 a-Pyrrolidinopropiophenone (a-PPP); or
8 Any other synthetic cathinone which is not approved by the
9 United States Food and Drug Administration or, if approved, is
10 not dispensed or possessed in accordance with State or federal
11 law.
12 (i) Synthetic cannabinoids or piperazines. Any synthetic
13 cannabinoid or piperazine which is not approved by the United
14 States Food and Drug Administration or, if approved, which is
15 not dispensed or possessed in accordance with State and
16 federal law.
17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
19 8-14-18.)
20 (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401)
21 Sec. 401. Manufacture or delivery, or possession with
22 intent to manufacture or deliver, a controlled substance, a
23 counterfeit substance, or controlled substance analog. Except
24 as authorized by this Act, it is unlawful for any person
25 knowingly to manufacture or deliver, or possess with intent to
SB2089 - 24 - LRB103 27669 RLC 57233 b
SB2089- 25 -LRB103 27669 RLC 57233 b SB2089 - 25 - LRB103 27669 RLC 57233 b
SB2089 - 25 - LRB103 27669 RLC 57233 b
1 manufacture or deliver, a controlled substance other than
2 methamphetamine and other than bath salts as defined in the
3 Bath Salts Prohibition Act sold or offered for sale in a retail
4 mercantile establishment as defined in Section 16-0.1 of the
5 Criminal Code of 2012, a counterfeit substance, or a
6 controlled substance analog. A violation of this Act with
7 respect to each of the controlled substances listed herein
8 constitutes a single and separate violation of this Act. For
9 purposes of this Section, "controlled substance analog" or
10 "analog" means a substance, other than a controlled substance,
11 which is not approved by the United States Food and Drug
12 Administration or, if approved, is not dispensed or possessed
13 in accordance with State or federal law, and that has a
14 chemical structure substantially similar to that of a
15 controlled substance in Schedule I or II, or that was
16 specifically designed to produce an effect substantially
17 similar to that of a controlled substance in Schedule I or II.
18 Examples of chemical classes in which controlled substance
19 analogs are found include, but are not limited to, the
20 following: phenethylamines, N-substituted piperidines,
21 morphinans, ecgonines, quinazolinones, substituted indoles,
22 and arylcycloalkylamines. For purposes of this Act, a
23 controlled substance analog shall be treated in the same
24 manner as the controlled substance to which it is
25 substantially similar.
26 (a) Any person who violates this Section with respect to
SB2089 - 25 - LRB103 27669 RLC 57233 b
SB2089- 26 -LRB103 27669 RLC 57233 b SB2089 - 26 - LRB103 27669 RLC 57233 b
SB2089 - 26 - LRB103 27669 RLC 57233 b
1 the following amounts of controlled or counterfeit substances
2 or controlled substance analogs, notwithstanding any of the
3 provisions of subsections (c), (d), (e), (f), (g) or (h) to the
4 contrary, is guilty of a Class X felony and shall be sentenced
5 to a term of imprisonment as provided in this subsection (a)
6 and fined as provided in subsection (b):
7 (1)(A) not less than 6 years and not more than 30 years
8 with respect to 15 grams or more but less than 100 grams of
9 a substance containing heroin, or an analog thereof;
10 (B) not less than 9 years and not more than 40 years
11 with respect to 100 grams or more but less than 400 grams
12 of a substance containing heroin, or an analog thereof;
13 (C) not less than 12 years and not more than 50 years
14 with respect to 400 grams or more but less than 900 grams
15 of a substance containing heroin, or an analog thereof;
16 (D) not less than 15 years and not more than 60 years
17 with respect to 900 grams or more of any substance
18 containing heroin, or an analog thereof;
19 (1.5)(A) not less than 6 years and not more than 30
20 years with respect to 15 grams or more but less than 100
21 grams of a substance containing fentanyl or xylazine, or
22 an analog thereof;
23 (B) not less than 9 years and not more than 40 years
24 with respect to 100 grams or more but less than 400 grams
25 of a substance containing fentanyl or xylazine, or an
26 analog thereof;
SB2089 - 26 - LRB103 27669 RLC 57233 b
SB2089- 27 -LRB103 27669 RLC 57233 b SB2089 - 27 - LRB103 27669 RLC 57233 b
SB2089 - 27 - LRB103 27669 RLC 57233 b
1 (C) not less than 12 years and not more than 50 years
2 with respect to 400 grams or more but less than 900 grams
3 of a substance containing fentanyl or xylazine, or an
4 analog thereof;
5 (D) not less than 15 years and not more than 60 years
6 with respect to 900 grams or more of a substance
7 containing fentanyl or xylazine, or an analog thereof;
8 (2)(A) not less than 6 years and not more than 30 years
9 with respect to 15 grams or more but less than 100 grams of
10 a substance containing cocaine, or an analog thereof;
11 (B) not less than 9 years and not more than 40 years
12 with respect to 100 grams or more but less than 400 grams
13 of a substance containing cocaine, or an analog thereof;
14 (C) not less than 12 years and not more than 50 years
15 with respect to 400 grams or more but less than 900 grams
16 of a substance containing cocaine, or an analog thereof;
17 (D) not less than 15 years and not more than 60 years
18 with respect to 900 grams or more of any substance
19 containing cocaine, or an analog thereof;
20 (3)(A) not less than 6 years and not more than 30 years
21 with respect to 15 grams or more but less than 100 grams of
22 a substance containing morphine, or an analog thereof;
23 (B) not less than 9 years and not more than 40 years
24 with respect to 100 grams or more but less than 400 grams
25 of a substance containing morphine, or an analog thereof;
26 (C) not less than 12 years and not more than 50 years
SB2089 - 27 - LRB103 27669 RLC 57233 b
SB2089- 28 -LRB103 27669 RLC 57233 b SB2089 - 28 - LRB103 27669 RLC 57233 b
SB2089 - 28 - LRB103 27669 RLC 57233 b
1 with respect to 400 grams or more but less than 900 grams
2 of a substance containing morphine, or an analog thereof;
3 (D) not less than 15 years and not more than 60 years
4 with respect to 900 grams or more of a substance
5 containing morphine, or an analog thereof;
6 (4) 200 grams or more of any substance containing
7 peyote, or an analog thereof;
8 (5) 200 grams or more of any substance containing a
9 derivative of barbituric acid or any of the salts of a
10 derivative of barbituric acid, or an analog thereof;
11 (6) 200 grams or more of any substance containing
12 amphetamine or any salt of an optical isomer of
13 amphetamine, or an analog thereof;
14 (6.5) (blank);
15 (6.6) (blank);
16 (7)(A) not less than 6 years and not more than 30 years
17 with respect to: (i) 15 grams or more but less than 100
18 grams of a substance containing lysergic acid diethylamide
19 (LSD), or an analog thereof, or (ii) 15 or more objects or
20 15 or more segregated parts of an object or objects but
21 less than 200 objects or 200 segregated parts of an object
22 or objects containing in them or having upon them any
23 amounts of any substance containing lysergic acid
24 diethylamide (LSD), or an analog thereof;
25 (B) not less than 9 years and not more than 40 years
26 with respect to: (i) 100 grams or more but less than 400
SB2089 - 28 - LRB103 27669 RLC 57233 b
SB2089- 29 -LRB103 27669 RLC 57233 b SB2089 - 29 - LRB103 27669 RLC 57233 b
SB2089 - 29 - LRB103 27669 RLC 57233 b
1 grams of a substance containing lysergic acid diethylamide
2 (LSD), or an analog thereof, or (ii) 200 or more objects or
3 200 or more segregated parts of an object or objects but
4 less than 600 objects or less than 600 segregated parts of
5 an object or objects containing in them or having upon
6 them any amount of any substance containing lysergic acid
7 diethylamide (LSD), or an analog thereof;
8 (C) not less than 12 years and not more than 50 years
9 with respect to: (i) 400 grams or more but less than 900
10 grams of a substance containing lysergic acid diethylamide
11 (LSD), or an analog thereof, or (ii) 600 or more objects or
12 600 or more segregated parts of an object or objects but
13 less than 1500 objects or 1500 segregated parts of an
14 object or objects containing in them or having upon them
15 any amount of any substance containing lysergic acid
16 diethylamide (LSD), or an analog thereof;
17 (D) not less than 15 years and not more than 60 years
18 with respect to: (i) 900 grams or more of any substance
19 containing lysergic acid diethylamide (LSD), or an analog
20 thereof, or (ii) 1500 or more objects or 1500 or more
21 segregated parts of an object or objects containing in
22 them or having upon them any amount of a substance
23 containing lysergic acid diethylamide (LSD), or an analog
24 thereof;
25 (7.5)(A) not less than 6 years and not more than 30 years
26 with respect to: (i) 15 grams or more but less than 100
SB2089 - 29 - LRB103 27669 RLC 57233 b
SB2089- 30 -LRB103 27669 RLC 57233 b SB2089 - 30 - LRB103 27669 RLC 57233 b
SB2089 - 30 - LRB103 27669 RLC 57233 b
1 grams of a substance listed in paragraph (1), (2), (2.1),
2 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
3 (26) of subsection (d) of Section 204, or an analog or
4 derivative thereof, or (ii) 15 or more pills, tablets,
5 caplets, capsules, or objects but less than 200 pills,
6 tablets, caplets, capsules, or objects containing in them
7 or having upon them any amounts of any substance listed in
8 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
9 (20.1), (21), (25), or (26) of subsection (d) of Section
10 204, or an analog or derivative thereof;
11 (B) not less than 9 years and not more than 40 years
12 with respect to: (i) 100 grams or more but less than 400
13 grams of a substance listed in paragraph (1), (2), (2.1),
14 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
15 (26) of subsection (d) of Section 204, or an analog or
16 derivative thereof, or (ii) 200 or more pills, tablets,
17 caplets, capsules, or objects but less than 600 pills,
18 tablets, caplets, capsules, or objects containing in them
19 or having upon them any amount of any substance listed in
20 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
21 (20.1), (21), (25), or (26) of subsection (d) of Section
22 204, or an analog or derivative thereof;
23 (C) not less than 12 years and not more than 50 years
24 with respect to: (i) 400 grams or more but less than 900
25 grams of a substance listed in paragraph (1), (2), (2.1),
26 (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
SB2089 - 30 - LRB103 27669 RLC 57233 b
SB2089- 31 -LRB103 27669 RLC 57233 b SB2089 - 31 - LRB103 27669 RLC 57233 b
SB2089 - 31 - LRB103 27669 RLC 57233 b
1 (26) of subsection (d) of Section 204, or an analog or
2 derivative thereof, or (ii) 600 or more pills, tablets,
3 caplets, capsules, or objects but less than 1,500 pills,
4 tablets, caplets, capsules, or objects containing in them
5 or having upon them any amount of any substance listed in
6 paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
7 (20.1), (21), (25), or (26) of subsection (d) of Section
8 204, or an analog or derivative thereof;
9 (D) not less than 15 years and not more than 60 years
10 with respect to: (i) 900 grams or more of any substance
11 listed in paragraph (1), (2), (2.1), (2.2), (3), (14.1),
12 (19), (20), (20.1), (21), (25), or (26) of subsection (d)
13 of Section 204, or an analog or derivative thereof, or
14 (ii) 1,500 or more pills, tablets, caplets, capsules, or
15 objects containing in them or having upon them any amount
16 of a substance listed in paragraph (1), (2), (2.1), (2.2),
17 (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
18 subsection (d) of Section 204, or an analog or derivative
19 thereof;
20 (8) 30 grams or more of any substance containing
21 pentazocine or any of the salts, isomers and salts of
22 isomers of pentazocine, or an analog thereof;
23 (9) 30 grams or more of any substance containing
24 methaqualone or any of the salts, isomers and salts of
25 isomers of methaqualone, or an analog thereof;
26 (10) 30 grams or more of any substance containing
SB2089 - 31 - LRB103 27669 RLC 57233 b
SB2089- 32 -LRB103 27669 RLC 57233 b SB2089 - 32 - LRB103 27669 RLC 57233 b
SB2089 - 32 - LRB103 27669 RLC 57233 b
1 phencyclidine or any of the salts, isomers and salts of
2 isomers of phencyclidine (PCP), or an analog thereof;
3 (10.5) 30 grams or more of any substance containing
4 ketamine or any of the salts, isomers and salts of isomers
5 of ketamine, or an analog thereof;
6 (10.6) 100 grams or more of any substance containing
7 hydrocodone, or any of the salts, isomers and salts of
8 isomers of hydrocodone, or an analog thereof;
9 (10.7) (blank);
10 (10.8) 100 grams or more of any substance containing
11 dihydrocodeine, or any of the salts, isomers and salts of
12 isomers of dihydrocodeine, or an analog thereof;
13 (10.9) 100 grams or more of any substance containing
14 oxycodone, or any of the salts, isomers and salts of
15 isomers of oxycodone, or an analog thereof;
16 (11) 200 grams or more of any substance containing any
17 other controlled substance classified in Schedules I or
18 II, or an analog thereof, which is not otherwise included
19 in this subsection.
20 (b) Any person sentenced with respect to violations of
21 paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
22 involving 100 grams or more of the controlled substance named
23 therein, may in addition to the penalties provided therein, be
24 fined an amount not more than $500,000 or the full street value
25 of the controlled or counterfeit substance or controlled
26 substance analog, whichever is greater. The term "street
SB2089 - 32 - LRB103 27669 RLC 57233 b
SB2089- 33 -LRB103 27669 RLC 57233 b SB2089 - 33 - LRB103 27669 RLC 57233 b
SB2089 - 33 - LRB103 27669 RLC 57233 b
1 value" shall have the meaning ascribed in Section 110-5 of the
2 Code of Criminal Procedure of 1963. Any person sentenced with
3 respect to any other provision of subsection (a), may in
4 addition to the penalties provided therein, be fined an amount
5 not to exceed $500,000.
6 (b-1) Excluding violations of this Act when the controlled
7 substance is fentanyl, any person sentenced to a term of
8 imprisonment with respect to violations of Section 401, 401.1,
9 405, 405.1, 405.2, or 407, when the substance containing the
10 controlled substance contains any amount of fentanyl, 3 years
11 shall be added to the term of imprisonment imposed by the
12 court, and the maximum sentence for the offense shall be
13 increased by 3 years.
14 (c) Any person who violates this Section with regard to
15 the following amounts of controlled or counterfeit substances
16 or controlled substance analogs, notwithstanding any of the
17 provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
18 to the contrary, is guilty of a Class 1 felony. The fine for
19 violation of this subsection (c) shall not be more than
20 $250,000:
21 (1) 1 gram or more but less than 15 grams of any
22 substance containing heroin, or an analog thereof;
23 (1.5) 1 gram or more but less than 15 grams of any
24 substance containing fentanyl, or an analog thereof;
25 (2) 1 gram or more but less than 15 grams of any
26 substance containing cocaine, or an analog thereof;
SB2089 - 33 - LRB103 27669 RLC 57233 b
SB2089- 34 -LRB103 27669 RLC 57233 b SB2089 - 34 - LRB103 27669 RLC 57233 b
SB2089 - 34 - LRB103 27669 RLC 57233 b
1 (2.5) 1 gram or more but less than 15 grams of any
2 substance containing xylazine, or an analog thereof;
3 (3) 10 grams or more but less than 15 grams of any
4 substance containing morphine, or an analog thereof;
5 (4) 50 grams or more but less than 200 grams of any
6 substance containing peyote, or an analog thereof;
7 (5) 50 grams or more but less than 200 grams of any
8 substance containing a derivative of barbituric acid or
9 any of the salts of a derivative of barbituric acid, or an
10 analog thereof;
11 (6) 50 grams or more but less than 200 grams of any
12 substance containing amphetamine or any salt of an optical
13 isomer of amphetamine, or an analog thereof;
14 (6.5) (blank);
15 (7)(i) 5 grams or more but less than 15 grams of any
16 substance containing lysergic acid diethylamide (LSD), or
17 an analog thereof, or (ii) more than 10 objects or more
18 than 10 segregated parts of an object or objects but less
19 than 15 objects or less than 15 segregated parts of an
20 object containing in them or having upon them any amount
21 of any substance containing lysergic acid diethylamide
22 (LSD), or an analog thereof;
23 (7.5)(i) 5 grams or more but less than 15 grams of any
24 substance listed in paragraph (1), (2), (2.1), (2.2), (3),
25 (14.1), (19), (20), (20.1), (21), (25), or (26) of
26 subsection (d) of Section 204, or an analog or derivative
SB2089 - 34 - LRB103 27669 RLC 57233 b
SB2089- 35 -LRB103 27669 RLC 57233 b SB2089 - 35 - LRB103 27669 RLC 57233 b
SB2089 - 35 - LRB103 27669 RLC 57233 b
1 thereof, or (ii) more than 10 pills, tablets, caplets,
2 capsules, or objects but less than 15 pills, tablets,
3 caplets, capsules, or objects containing in them or having
4 upon them any amount of any substance listed in paragraph
5 (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
6 (21), (25), or (26) of subsection (d) of Section 204, or an
7 analog or derivative thereof;
8 (8) 10 grams or more but less than 30 grams of any
9 substance containing pentazocine or any of the salts,
10 isomers and salts of isomers of pentazocine, or an analog
11 thereof;
12 (9) 10 grams or more but less than 30 grams of any
13 substance containing methaqualone or any of the salts,
14 isomers and salts of isomers of methaqualone, or an analog
15 thereof;
16 (10) 10 grams or more but less than 30 grams of any
17 substance containing phencyclidine or any of the salts,
18 isomers and salts of isomers of phencyclidine (PCP), or an
19 analog thereof;
20 (10.5) 10 grams or more but less than 30 grams of any
21 substance containing ketamine or any of the salts, isomers
22 and salts of isomers of ketamine, or an analog thereof;
23 (10.6) 50 grams or more but less than 100 grams of any
24 substance containing hydrocodone, or any of the salts,
25 isomers and salts of isomers of hydrocodone, or an analog
26 thereof;
SB2089 - 35 - LRB103 27669 RLC 57233 b
SB2089- 36 -LRB103 27669 RLC 57233 b SB2089 - 36 - LRB103 27669 RLC 57233 b
SB2089 - 36 - LRB103 27669 RLC 57233 b
1 (10.7) (blank);
2 (10.8) 50 grams or more but less than 100 grams of any
3 substance containing dihydrocodeine, or any of the salts,
4 isomers and salts of isomers of dihydrocodeine, or an
5 analog thereof;
6 (10.9) 50 grams or more but less than 100 grams of any
7 substance containing oxycodone, or any of the salts,
8 isomers and salts of isomers of oxycodone, or an analog
9 thereof;
10 (11) 50 grams or more but less than 200 grams of any
11 substance containing a substance classified in Schedules I
12 or II, or an analog thereof, which is not otherwise
13 included in this subsection.
14 (c-5) (Blank).
15 (d) Any person who violates this Section with regard to
16 any other amount of a controlled or counterfeit substance
17 containing dihydrocodeine or classified in Schedules I or II,
18 or an analog thereof, which is (i) a narcotic drug, (ii)
19 lysergic acid diethylamide (LSD) or an analog thereof, (iii)
20 any substance containing amphetamine or fentanyl or xylazine
21 or any salt or optical isomer of amphetamine or fentanyl or
22 xylazine, or an analog thereof, or (iv) any substance
23 containing N-Benzylpiperazine (BZP) or any salt or optical
24 isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
25 guilty of a Class 2 felony. The fine for violation of this
26 subsection (d) shall not be more than $200,000.
SB2089 - 36 - LRB103 27669 RLC 57233 b
SB2089- 37 -LRB103 27669 RLC 57233 b SB2089 - 37 - LRB103 27669 RLC 57233 b
SB2089 - 37 - LRB103 27669 RLC 57233 b
1 (d-5) (Blank).
2 (e) Any person who violates this Section with regard to
3 any other amount of a controlled substance other than
4 methamphetamine or counterfeit substance classified in
5 Schedule I or II, or an analog thereof, which substance is not
6 included under subsection (d) of this Section, is guilty of a
7 Class 3 felony. The fine for violation of this subsection (e)
8 shall not be more than $150,000.
9 (f) Any person who violates this Section with regard to
10 any other amount of a controlled or counterfeit substance
11 classified in Schedule III is guilty of a Class 3 felony. The
12 fine for violation of this subsection (f) shall not be more
13 than $125,000.
14 (g) Any person who violates this Section with regard to
15 any other amount of a controlled or counterfeit substance
16 classified in Schedule IV is guilty of a Class 3 felony. The
17 fine for violation of this subsection (g) shall not be more
18 than $100,000.
19 (h) Any person who violates this Section with regard to
20 any other amount of a controlled or counterfeit substance
21 classified in Schedule V is guilty of a Class 3 felony. The
22 fine for violation of this subsection (h) shall not be more
23 than $75,000.
24 (i) This Section does not apply to the manufacture,
25 possession or distribution of a substance in conformance with
26 the provisions of an approved new drug application or an
SB2089 - 37 - LRB103 27669 RLC 57233 b
SB2089- 38 -LRB103 27669 RLC 57233 b SB2089 - 38 - LRB103 27669 RLC 57233 b
SB2089 - 38 - LRB103 27669 RLC 57233 b
1 exemption for investigational use within the meaning of
2 Section 505 of the Federal Food, Drug and Cosmetic Act.
3 (j) (Blank).
4 (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17;
5 100-368, eff. 1-1-18.)
SB2089 - 38 - LRB103 27669 RLC 57233 b